Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Dr. Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Dr. Nikolaos Marinakis,  Laboratory of Medical Genetics, NKUA, Greece.

Dr. Nikolaos M. Marinakis is a highly accomplished Molecular Biologist and Geneticist whose career has been devoted to the diagnosis and molecular analysis of rare genetic disorders. With over a decade of laboratory experience and a strong academic background, he has steadily advanced from early bench research in molecular biology to become a Clinical Laboratory Geneticist and genome analyst. His expertise spans whole exome and whole genome sequencing, variant interpretation, CNV and RNA sequencing analysis, and the clinical application of Next Generation Sequencing. Notably, he has contributed to over 1500 molecular diagnoses in patients with rare diseases and has gained international recognition through the ESHG observership at Radboud University Medical Center. Dr. Marinakis exemplifies scientific excellence, clinical impact, and collaborative innovation in human genetics.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Dr. Nikolaos M. Marinakis embarked on his academic journey with a strong passion for understanding human biology at a molecular level. He earned his Bachelor’s degree in Molecular Biology and Genetics from the Democritus University of Thrace (DUTH), where he was actively involved in bench research. His undergraduate thesis focused on the functional characterization of NAT1 polymorphisms in the primate Macaca mulatta, offering an early glimpse into his interest in gene function and enzyme activity. This formative research cultivated his technical proficiency in cloning, site-directed mutagenesis, protein purification, and enzymatic assays—skills that would later become instrumental in his advanced academic and clinical endeavors.

🧬 Professional Endeavors in Genetics

Dr. Marinakis has spent more than a decade immersed in both research and clinical laboratories, gaining broad and deep expertise in molecular diagnostics. His professional foundation was laid at the Laboratory of Medical Genetics at St. Sophia’s Children Hospital, affiliated with the National and Kapodistrian University of Athens (NKUA). Here, he progressed from an MSc student to a PhD candidate and eventually to a Scientific Research Associate. His doctoral research was centered on the use of Next Generation Sequencing (NGS) technologies for diagnosing rare genetic disorders, and his project involved bioinformatic evaluation and functional validation of genomic variants. As a current genome analyst, he supervises Clinical Whole Exome Sequencing, routinely interpreting variants in over 1,500 complex diagnostic cases encompassing neurodevelopmental, nephrological, cardiovascular, and ophthalmological diseases.

🔍 Research Contributions and Focus

Dr. Marinakis’s primary research lies at the intersection of clinical genomics and bioinformatics. His scientific focus is on the molecular investigation of rare monogenic disorders, variant classification, and the integration of novel genomic technologies such as long-read sequencing into diagnostic pipelines. He has also contributed to the development and clinical implementation of molecular assays for both postnatal and prenatal diagnostics. His research continues to unravel the genetic underpinnings of syndromes with previously unknown etiologies, enriching the understanding of human genomic complexity. Through RNA sequencing and CNV analysis, he bridges the gap between genotype and phenotype in a clinical context.

🏅 Accolades and Recognition

In recognition of his significant contributions to human genetics, Dr. Marinakis was awarded a competitive observership by the European Society of Human Genetics (ESHG). This prestigious award enabled him to join the Genome Diagnostics unit at the Radboud University Medical Center in the Netherlands under the mentorship of Professor Christian Gilissen. There, he expanded his expertise in whole genome sequencing, variant annotation, structural variation, and advanced bioinformatic pipelines. His growing recognition as a Clinical Laboratory Geneticist (ErCLG-certified) further underscores his professional standing in Europe’s genetics community.

🧠 Impact on Clinical Genomics

Dr. Marinakis has made a measurable impact on translational medicine by bringing genomic science to the bedside. Through his analysis and interpretation of complex NGS datasets, he has helped diagnose hundreds of patients with elusive genetic conditions, directly improving clinical outcomes and enabling personalized treatment strategies. His ability to convert raw genomic data into meaningful clinical insights has made him a key figure in the field of diagnostic genetics in Greece and beyond. His meticulous approach to variant interpretation, especially in challenging or ambiguous cases, continues to guide clinicians in the decision-making process.

🌍 Influence and Collaboration

A committed collaborator and lifelong learner, Dr. Marinakis maintains strong academic and clinical ties with global institutions. His experiences at NKUA and Radboud UMC have equipped him with a broad international outlook on genomics and rare disease research. He actively contributes to cross-border initiatives and research consortiums focused on data sharing, standardization of bioinformatics pipelines, and discovery of novel disease mechanisms. His LinkedIn presence and professional engagement reflect his dedication to connecting with the wider genetics and biomedical community.

🔮 Legacy and Future Contributions

Looking ahead, Dr. Marinakis is poised to lead initiatives that integrate AI-driven genomic interpretation and third-generation sequencing into clinical practice. He aspires to contribute to national and European genomics strategies aimed at early diagnosis, carrier screening, and reproductive planning. By mentoring younger scientists and continuing to publish translational research, he is building a legacy rooted in both scientific rigor and compassionate care. With his strong foundation and forward-thinking vision, Dr. Marinakis represents a dynamic force in the future of precision medicine and rare disease diagnostics.

Publication

  • Title: Phenotype‐driven variant filtration strategy in exome sequencing toward a high diagnostic yield and identification of 85 novel variants in 400 patients with rare Mendelian disorders
    Authors: NM Marinakis, M Svingou, D Veltra, K Kekou, C Sofocleous, FN Tilemis, …
    Year: 2021

 

  • Title: Germline CNV detection through whole-exome sequencing (WES) data analysis enhances resolution of rare genetic diseases
    Authors: FN Tilemis, NM Marinakis, D Veltra, M Svingou, K Kekou, A Mitrakos, …
    Year: 2023

 

  • Title: Case report: a novel synonymous ARPC1B gene mutation causes a syndrome of combined immunodeficiency, asthma, and allergy with significant intrafamilial clinical heterogeneity
    Authors: I Papadatou, N Marinakis, E Botsa, M Tzanoudaki, M Kanariou, I Orfanou, …
    Year: 2021

 

  • Title: The clinical and genetic spectrum of autosomal-recessive TOR1A-related disorders
    Authors: A Saffari, T Lau, H Tajsharghi, EG Karimiani, A Kariminejad, S Efthymiou, …
    Year: 2023

 

  • Title: Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals
    Authors: DE Layo-Carris, EE Lubin, AK Sangree, KJ Clark, EL Durham, …
    Year: 2024

 

  • Title: De novo variants in RNF213 are associated with a clinical spectrum ranging from Leigh syndrome to early-onset stroke
    Authors: T Brunet, B Zott, V Lieftüchter, D Lenz, A Schmidt, P Peters, R Kopajtich, …
    Year: 2024

 

  • Title: SDH-deficient renal cell carcinoma: A case report associated with a novel germline mutation
    Authors: V Milionis, D Goutas, D Vlachodimitropoulos, AC Lazaris, I Kyriazis, …
    Year: 2021

 

  • Title: Towards a standard benchmark for variant and gene prioritisation algorithms: PhEval-Phenotypic inference Evaluation framework
    Authors: Y Bridges, V de Souza, KG Cortes, M Haendel, NL Harris, DR Korn, …
    Year: 2024

 

  • Title: Bi-allelic genetic variants in the translational GTPases GTPBP1 and GTPBP2 cause a distinct identical neurodevelopmental syndrome
    Authors: V Salpietro, R Maroofian, MS Zaki, J Wangen, A Ciolfi, S Barresi, …
    Year: 2024

 

  • Title: Combined exome analysis and exome depth assessment achieve a high diagnostic yield in an epilepsy case series, revealing significant genomic heterogeneity and novel mechanisms
    Authors: D Veltra, FN Tilemis, NM Marinakis, M Svingou, A Mitrakos, K Kosma, …
    Year: 2023

 

✅ Conclusion

Dr. Nikolaos M. Marinakis stands out as a distinguished researcher in the field of medical genetics and genomics. His work bridges cutting-edge molecular research with clinical diagnostics, making a direct impact on patient care and the understanding of rare diseases. His technical expertise, international collaborations, and growing leadership in genomic diagnostics reflect both his current achievements and his potential for future contributions to precision medicine. He is a strong candidate for recognition in any academic or professional forum honoring excellence in translational genomics and biomedical research.

Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Assoc. Prof. Dr. Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Assoc. Prof. Dr. Izabela Małysz-Cymborska,  Department of Neurology and Neurosurgery, School of Medicine, University of Warmia and Mazury, Poland.

Dr. Izabela Małysz-Cymborska is a distinguished biomedical researcher and Associate Professor in Neurosurgery at the University of Warmia and Mazury, Poland. Her academic path began with a Master’s in Biology and culminated in a Ph.D. focused on hormonal mechanisms, followed by a Habilitation in Medicine. Her research spans neuroregeneration, stem cell therapy, and immunomodulatory strategies for neurological diseases such as ALS and stroke. She has led and contributed to nationally funded projects like NanoTech4ALS, Explore Me, and her current OPUS-funded investigation using a swine model for stroke therapy. Her interdisciplinary approach bridges molecular biology, reproductive science, and clinical neuroscience, demonstrating a rare ability to translate foundational research into therapeutic innovation.

Profile

Google Scholar

🎓 Early Academic Pursuits

Dr. Izabela Małysz-Cymborska embarked on her academic journey with a deep-rooted interest in biological sciences. Born on September 21, 1985, in Poland, she pursued her undergraduate studies at the University of Warmia and Mazury in Olsztyn, earning a Master of Science degree in Biology in 2009. Her passion for advanced biomedical research led her to the Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, where she completed her Ph.D. in 2015. Her doctoral research, grounded in hormonal action mechanisms, laid the foundation for her future contributions to neurobiology and regenerative medicine.

🧠 Professional Endeavors in Neuroscience

Dr. Małysz-Cymborska’s postdoctoral and professional journey has been largely rooted in neuroscientific investigation, with a special focus on neuroregeneration and stroke therapy. Since 2021, she has held the position of Associate Professor in the Department of Neurosurgery at the University of Warmia and Mazury. Her early postdoctoral fellowships (2015–2018) focused on pioneering work in the application of glial progenitors and stem cells in neurological disorders like ALS. These formative experiences not only enriched her research trajectory but also provided a vital bridge between animal studies and translational medicine.

🧪 Research Focus and Scientific Contributions

Dr. Małysz-Cymborska’s research portfolio reflects a consistent dedication to understanding complex neural pathologies and their treatment through regenerative approaches. She has led and contributed to several national and international projects, including NanoTech4ALS, which investigated MRI-monitored transplantation techniques using hydrogel carriers for ALS treatment. Her current role as Principal Investigator in the OPUS-funded project explores an endovascular model of stroke in swine, opening new therapeutic pathways for immunomodulation. She has also delved into reproductive biology, investigating the influence of gonadotropins on prostaglandin synthesis and the function of the corpus luteum, showcasing her multidisciplinary expertise.

🧬 Bridging Regeneration and Technology

A major hallmark of Dr. Małysz-Cymborska’s work is the integration of regenerative medicine and cutting-edge biomedical technologies. Her involvement in Explore Me and NanoTech4ALS demonstrated her commitment to merging cellular therapy with advanced biomaterials and imaging. These projects explored the therapeutic potential of mesenchymal stem cells and human glial progenitors for neurodegenerative conditions, reflecting her drive to push boundaries in translational medicine and neurosurgery.

🏅 Accolades and Recognition

Dr. Małysz-Cymborska’s scientific accomplishments were recognized through her Habilitation Degree in Medicine, awarded in 2022 by the University of Warmia and Mazury—a prestigious academic achievement in Poland that underscores her contributions to the medical sciences. Additionally, her appointment as the Dean’s representative for animal experiments between 2018 and 2019 further illustrates the trust and respect she commands within her institution and the research community.

🌍 Impact and Influence in Translational Neuroscience

Her work has had significant implications not only in Poland but also across the global neuroscience landscape. By focusing on models that simulate real-world human neurological disorders, such as swine models for stroke and ALS, she has established platforms that can more accurately predict treatment outcomes in humans. Her collaborative efforts within national strategic medical programs have enriched the broader field of translational neuroscience, particularly in immune response modulation and neural repair mechanisms.

🔮 Legacy and Future Contributions

As her OPUS project continues until 2025, Dr. Izabela Małysz-Cymborska is poised to deliver crucial insights into stroke immunotherapy. Her legacy lies in her ability to traverse boundaries between endocrinology, neurobiology, and regenerative therapy—crafting a unique niche that advances both fundamental science and clinical application. With a promising trajectory ahead, she is set to influence future protocols in neurovascular therapy, offering hope to patients with currently untreatable conditions.

Publication

  • Hydrogel-based scaffolds to support intrathecal stem cell transplantation as a gateway to the spinal cord: clinical needs, biomaterials, and imaging technologies
    Authors: JM Oliveira, L Carvalho, J Silva-Correia, S Vieira, M Majchrzak, …
    Year: 2018

 

  • Advances in bioinks and in vivo imaging of biomaterials for CNS applications
    Authors: EP Oliveira, I Malysz-Cymborska, D Golubczyk, L Kalkowski, …
    Year: 2019

 

  • The role of glia in canine degenerative myelopathy: relevance to human amyotrophic lateral sclerosis
    Authors: D Golubczyk, I Malysz-Cymborska, L Kalkowski, M Janowski, JR Coates, …
    Year: 2019

 

  • Methacrylated gellan gum and hyaluronic acid hydrogel blends for image-guided neurointerventions
    Authors: S Vieira, P Strymecka, L Stanaszek, J Silva-Correia, K Drela, …
    Year: 2020

 

  • MRI-guided intrathecal transplantation of hydrogel-embedded glial progenitors in large animals
    Authors: I Malysz-Cymborska, D Golubczyk, L Kalkowski, A Burczyk, M Janowski, …
    Year: 2018

 

  • Endovascular model of ischemic stroke in swine guided by real-time MRI
    Authors: D Golubczyk, L Kalkowski, J Kwiatkowska, M Zawadzki, P Holak, J Glodek, …
    Year: 2020

 

  • Expression of the vascular endothelial growth factor receptor system in porcine oviducts after induction of ovulation and superovulation
    Authors: I Małysz-Cymborska, A Andronowska
    Year: 2014

 

  • Rabbit model of human gliomas: implications for intra-arterial drug delivery
    Authors: H Qin, M Janowski, MS Pearl, I Malysz-Cymborska, S Li, CG Eberhart, …
    Year: 2017

 

  • Two in one: use of divalent manganese ions as both cross-linking and MRI contrast agent for intrathecal injection of hydrogel-embedded stem cells
    Authors: L Kalkowski, D Golubczyk, J Kwiatkowska, P Holak, K Milewska, …
    Year: 2021

 

  • Effect of hCG and eCG treatments on Prostaglandins Synthesis in the Porcine Oviduct
    Authors: I Małysz‐Cymborska, AJ Ziecik, A Waclawik, A Andronowska
    Year: 2013

 

🧾 Conclusion

Dr. Małysz-Cymborska’s career reflects a compelling fusion of scientific curiosity, clinical relevance, and academic rigor. With notable achievements in regenerative medicine and translational neuroscience, she continues to shape the future of therapeutic interventions for complex neurological disorders. Her ongoing research promises to pave the way for advanced stroke treatments and immune-based neurotherapies, cementing her role as a key contributor to modern biomedical science.

Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu, Exegenesis Bio, Inc ,United States.

Zhenhua Wu is a distinguished biotech entrepreneur and scientific leader with over 20 years of experience across the research and development value chain. As the founder, President, and CEO of Exegenesis Bio Inc., he has pioneered accessible, innovative gene therapies for patients with unmet medical needs. His journey spans rigorous academic beginnings, executive leadership in multiple biotechnology companies, and a steadfast commitment to global health advancement. Known for assembling world-class talent and making strategic decisions, Wu has played a key role in shaping the future of gene therapy through both scientific and business excellence.

Profile

Orcid

 

🎓 Early Academic Pursuits

Zhenhua Wu’s journey into the world of biotechnology and gene therapy was shaped by a solid academic foundation rooted in scientific rigor and innovation. During his early academic pursuits, he demonstrated a deep curiosity for biological systems and therapeutic sciences. This intellectual appetite laid the groundwork for his future endeavors in translational medicine, where scientific discovery meets real-world application. His academic training not only honed his research skills but also instilled a lifelong commitment to innovation in the life sciences.

💼 Professional Endeavors

With more than two decades of hands-on experience in the research and development value chain, Zhenhua Wu has established himself as a seasoned leader in biotechnology. He has served in executive roles across a range of biotech companies of various sizes and strategic focuses. In each capacity, he brought visionary leadership, guiding teams to deliver impactful solutions in the biomedical space. His career has been a progressive climb from scientific inquiry to corporate strategy, integrating a robust understanding of science with sharp business acumen.

🧬 Contributions and Research Focus

As a pioneer in the field of gene therapy, Zhenhua Wu’s contributions are both profound and multifaceted. He is the founder and current President and CEO of Exegenesis Bio Inc., a multinational gene therapy company based in Philadelphia, PA. Under his leadership, the company has developed a pipeline of innovative, affordable gene therapies designed to address high unmet medical needs. His research focus lies in advancing next-generation gene therapies that are not only effective but also accessible, aiming to bridge the gap between scientific breakthroughs and patient care.

🏆 Accolades and Recognition

Zhenhua Wu’s impactful career has earned him recognition as a visionary entrepreneur and scientific innovator. Though his biography remains modest in tone, his work has resonated across the biotech sector, attracting significant investment and strategic partnerships. His ability to build and lead a cutting-edge biotech company from the ground up has marked him as a key influencer in gene therapy, with accolades stemming from both industry peers and investors who recognize the value and promise of his work.

🌍 Impact and Influence

Through Exegenesis Bio, Zhenhua Wu has catalyzed a new wave of therapeutic innovation with global reach. His influence extends beyond the lab and boardroom, impacting regulatory conversations, patient advocacy movements, and international biotech development. By forging cross-continental collaborations and assembling a top-tier team of experts, he has ensured that the company is positioned as a global leader in gene therapy solutions, redefining what is possible in patient care and drug development.

🧭 Legacy and Future Contributions

Looking ahead, Zhenhua Wu continues to chart a path focused on expanding access to gene therapy on a global scale. His legacy is being built not only through the therapies under development but also through the culture of scientific integrity, innovation, and purpose that he has instilled in his company. He remains dedicated to mentoring future leaders, cultivating partnerships that push boundaries, and shaping a future where life-altering treatments are within reach for all who need them.

🧠 Visionary Leadership in Gene Therapy

At the heart of Zhenhua Wu’s professional identity is his role as a visionary leader in the fast-evolving field of gene therapy. His ability to connect scientific breakthroughs with patient-focused strategies has transformed Exegenesis Bio into a beacon of hope for countless individuals suffering from genetic diseases. Through his relentless pursuit of innovation, ethical leadership, and commitment to excellence, he continues to redefine what leadership means in the life sciences industry.

Publication

  • Title: Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions
    Authors: Ariazi J, Benowitz A, De Biasi V, den Boer M, Cherqui S, Cui H, Douillet N, Eugenin EA, Favre D, Goodman S, et al.
    Year: 2017

 

  • Title: Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats
    Authors: Wu G, Wu Z, Na S, Hershey JC
    Year: 2015

 

  • Title: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
    Authors: Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, et al.
    Year: 2005

 

🔚 Conclusion

Zhenhua Wu’s career reflects the powerful intersection of science, leadership, and purpose. From building a visionary biotech enterprise to steering the development of transformative therapies, his contributions continue to resonate across the scientific community and healthcare industry. His legacy is not only defined by the innovations he leads today but also by the future he is helping shape—one where advanced gene therapies are more equitable, effective, and globally impactful. Through unwavering dedication and strategic foresight, he stands as a beacon of inspiration in the world of modern biotechnology.